On September 27, Huadong Medicine announced that its independently developed Class 1 innovative drug, the oral small-molecule ...

Lipfendra and promising intismeran autogene trial results support Merck's multi-year portfolio renewal prospects amid patent ...

Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular ...

Dechra, a global leader in veterinary specialty care, today announced the availability of Laverdia® (verdinexor tablets), the first and only FDA-approved oral treatment for dogs diagnosed with ...

NVO tumbled about 8% as its Capital Markets Day failed to convince investors despite plans for more than five “multi-blockbusters” by 2030. ・Viking’s injectable VK2735 produced up to 14.7% weight loss ...

AstraZeneca PLC is a high-quality compounder leveraging mid-single-digit revenue growth into robust EPS gains. Read why AZN ...

Novo Nordisk (NVO) stock fell 9% as the drugmaker unveiled 2030 growth targets, five-plus blockbuster launches and a $23 ...

Novo Nordisk shares fell as much as 6% on Monday after the Danish drugmaker's ambitious growth targets aimed at reviving its fortunes in the increasingly competitive obesity drug market failed to ...

AURORA, CO / ACCESS Newswire / September 22, 2026 / Rezera Inc. (the "Company"), a clinical-stage biotechnology company ...

VigorHorse new botanical supplement combines multiple plant extracts, L-arginine and a small amount of caffeine in a once-daily gummy format ...

A new oral treatment gives veterinarians and pet owners another option to consider following a canine lymphoma diagnosis.

Novo Nordisk (NVO) shares dropped 9% Monday after revealing 2030 growth targets aligned with pharma peers and plans for five new blockbuster drug launches.